Initiatives include mouth rinse, patient management software to better treat bipolar disorder
LEXINGTON, Ky. (Feb. 1, 2013) — Biomedical Development Corp. (BDC) is expanding its operations to Lexington. A 28 year-old company from San Antonio, BDC has secured two grants from the Kentucky SBIR-STTR Matching Funds Program. Aligned with the innovative grant program and the University of Kentucky, BDC aims to extend its successful record investing in healthcare technologies.
The expansion is “…an opportunity to bring new products to the market,” said company founder and CEO Phyllis Siegel. “Kentucky has provided some very forward-thinking financial and programming incentives for Biomedical to move here because of the commercial potential of our products and the expertise of the company. We are meeting members of an open and progressive startup community and look forward to being part of the regional ecosystem.”
The mouth rinse will be tested in an upcoming trial in collaboration with the Center for Oral Health Research at the University of Kentucky in Lexington. The mouth rinse fights oral inflammation and may lower high cholesterol. It has been previously tested in three human clinical trials. The fourth trial began last month. This research is funded by the National Heart, Lung and Blood Institute.
KIOS Health, the patient management software, provides real time support for bipolar patients, doctors, and caregivers. The product will provide expert advice based on the individualized trajectory of a patient’s disease course. This will enable patients to have greater control over their health.
An Internet-based application is being developed and will be tested in early 2013. This research is funded by the National Institute of Mental Health; Charles L. Bowden, MD. and H. Richard Priesmeyer, Ph.D. are principal investigators.
BDC’s Kentucky office is located in Lexington, in the ASTeCC building on the University of Kentucky’s campus.
news from across Kentucky